A Phase 3 interventional study of TNX-102 SL in Primary Fibromyalgia, sponsored by Tonix Pharmaceuticals, Inc.. Completed at 13 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-07-07.
Sponsored by Tonix Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 369 studies in Fibromyalgia with a site in United States — 52 open to participants now, 63 under way, 2 of them phase 3. Fibromyalgia · United States.
Among the 369 studies in Fibromyalgia with a site in United States, this one is the 100th largest by enrollment of the 320 interventional ones that give a count, is one of 13 that started in 2013, is one of 55 in phase 3, and was the 188th registered.
1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
Browse Fibromyalgia studies →52 of the 369 studies in Fibromyalgia with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 14–26
Spaulding Rehabilitation Hospital · Sites in United States
Ages 21–65
Pulkit Grover · Sites in United States
Ages 18–65
Theranica · Sites in United States, Israel
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
369 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 61 · Phase 3 64 · Phase 4 24
First in 1994; this study’s year is marked. 13 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 158 is above the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Median enrollment 72 across the 320 interventional studies, 200 across the 47 observational. Of the 276 that completed or were terminated, 116 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
101 of 369 have an industry lead sponsor. The 10 most frequent:
Tonix Pharmaceuticals, Inc. is the lead sponsor of 34 studies on the registry; 1 is open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 12 (71%) have results posted.
Tonix Pharmaceuticals, Inc. has 8 studies filed under Fibromyalgia — fewer than ten, so there is no comparison to draw.
29 of the studies in Fibromyalgia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02979574Memorial Sloan Kettering Cancer CenterPEACE: Comparing Chronic Pain Treatment Options | 2026-11 |
| NCT07116278University of California, San FranciscoTMS-EEG Biomarkers for Chronic Pain | 2026-12 |
| NCT04949100Paul CrawfordMicrocurrent for Fibromyalgia | 2026-12 |
| NCT07525063Duke UniversityPain & Reward Neuromodulation of CNS Circuits | 2026-12 |
| NCT06552728University of California, IrvineThe Effects of Energy Healing in Fibromyalgia | 2026-12 |
Add all 29 to your calendar (.ics) → With an account.
Among the 369 studies in Fibromyalgia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was an open-label, extension trial designed to evaluate the long-term safety over 12 months of TNX-102 SL tablets taken daily at bedtime for the treatment of fibromyalgia. Patients recruited into this trial were those who had successfully completed the double-blind study, TNX-CY-F202 (F202) (NCT01903265). Patients were not made aware of the therapy they received during the double-blind study.
The study consisted of 7 clinic visits, including Screening/Baseline Visit 1 (Day 0 which was typically the same date as Visit 6 of the double-blind lead-in study), visits after 1, 3, 6, 9, and 12 months of treatment (Visits 2-6), and a Follow-up Visit (Visit 7) scheduled within one month after stopping study drug treatment.
Primary:
The primary objective of the study was to evaluate the long-term safety of TNX-102 SL tablets taken daily at bedtime over 12 months in patients with fibromyalgia who have completed Study TNX-CY-F202 (NCT01903265)
Secondary:
The secondary objective was to evaluate the long-term efficacy of TNX-102 SL tablets taken daily at bedtime to control symptoms of fibromyalgia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
None
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1x TNX-102 SL 2.8 mg sublingual tablet taken daily at bedtime for 12 months
Drug: TNX-102 SL
TNX-102 SL 2.8 mg taken daily at bedtime.
Also known as: cyclobenzaprine HCl
Newly-emergent Adverse Events (NEAEs) During Treatment With TNX-102 SL Tablets Taken Daily at Bedtime Over 12 Months in Patients With Fibromyalgia.
NEAEs and Serious Adverse events (SAEs) were collected and are coded using the latest version of the Medical Dictionary for Regulatory Activities (MedDRA).
Time frame: Up to 12 months
Change From Baseline in Numerical Rating Scale (NRS) Assessments of Average Pain Based on 24 Hour Recall
The NRS for average pain was an 11-point scale (0=no pain → 10=worst pain imaginable) that was assessed on a 24-hour recall basis.
Time frame: Months 1, 3, 6, 9 and 12.
Change From Baseline in Numerical Rating Scale (NRS) Assessments of Average Pain Based on a 7 Day Recall
The NRS for average pain over the past 7 days was an 11-point scale (0=no pain → 10=worst pain imaginable) that was assessed on a 7-day recall basis.
Time frame: Month 1, 3, 6, 9, 12
Responder Analysis of Patient's Global Impression of Change (PGIC)
PGIC is a fibromyalgia-specific validated instrument to gauge the patient's assessment of change in condition.The scores are categorized as provided below. A responder was defined by a score of 1 (very much improved), or 2 (much improved). 1. = Very much improved 2. = Much improved 3. = Minimally improved 4. = No change 5. = Minimally worse 6. = Much worse 7. = Very much worse
Time frame: Months 1, 3, 6, 9, 12
One hundred fifty-eight (158) of the 174 patients who completed 12 weeks of treatment in Study F202 were eligible and consented to participate in the 12-month safety extension study.
| Milestone | Placebo - TNX-102 SL 2.8 mg | TNX-102 SL 2.8mg - TNX-102 SL 2.8 mg |
|---|---|---|
| Started | 79 | 79 |
| Completed | 43 | 54 |
| Not completed | 36 | 25 |
NEAEs and Serious Adverse events (SAEs) were collected and are coded using the latest version of the Medical Dictionary for Regulatory Activities (MedDRA).
| Participants | Placebo - TNX-102 SL 2.8 mg | TNX-102 SL 2.8 mg - TNX-102 SL 2.8 mg |
|---|---|---|
| Patient with at least 1 NEAE reported | 60 | 54 |
| Patients withdrew due to NEAE | 18 | 9 |
| Patient with at least 1 SAE | 3 | 5 |
The NRS for average pain was an 11-point scale (0=no pain → 10=worst pain imaginable) that was assessed on a 24-hour recall basis.
| Scores on a scale | Placebo - TNX-102 SL 2.8 mg | TNX-102 SL 2.8 mg - TNX-102 SL 2.8 mg |
|---|---|---|
| Baseline | 5.6 ± 2.29 | 5.0 ± 2.52 |
| Change at Month 1 | -0.5 ± 1.96 | -0.2 ± 1.75 |
| Change at Month 3 | -0.5 ± 1.86 | -0.3 ± 1.92 |
| Change at Month 6 | -0.7 ± 2.18 | -0.2 ± 2.32 |
| Change at Month 9 | -0.6 ± 2.36 | 0.0 ± 1.91 |
| Change at Month 12 | 0.1 ± 2.08 | -0.0 ± 2.26 |
The NRS for average pain over the past 7 days was an 11-point scale (0=no pain → 10=worst pain imaginable) that was assessed on a 7-day recall basis.
| Scores on a scale | Placebo - TNX-102 SL 2.8 mg | TNX-102 SL 2.8 mg - TNX-102 SL 2.8 mg |
|---|---|---|
| Baseline | 5.7 ± 2.09 | 4.8 ± 2.18 |
| Change at Month 1 | -0.8 ± 1.68 | 0.1 ± 1.13 |
| Change at Month 3 | -0.6 ± 1.67 | 0.1 ± 1.85 |
| Change at Month 6 | -0.7 ± 2.06 | 0.2 ± 2.11 |
| Change at Month 9 | -0.4 ± 2.33 | 0.0 ± 2.07 |
| Change at Month 12 | 0.0 ± 1.72 | 0.2 ± 1.84 |
PGIC is a fibromyalgia-specific validated instrument to gauge the patient's assessment of change in condition.The scores are categorized as provided below. A responder was defined by a score of 1 (very much improved), or 2 (much improved). 1. = Very much improved 2. = Much improved 3. = Minimally improved 4. = No change 5. = Minimally worse 6. = Much worse 7. = Very much worse
| Participants | Placebo - TNX-102 SL 2.8 mg | TNX-102 SL 2.8mg - TNX-102 SL 2.8 mg |
|---|---|---|
| Month 1 — Score 1 or 2 | 16 | 25 |
| Month 1 — Scores 3 to 7 | 63 | 54 |
| Month 3 — Score 1 or 2 | 23 | 29 |
| Month 3 — Scores 3 to 7 | 56 | 50 |
| Month 6 — Score 1 or 2 | 22 | 26 |
| Month 6 — Scores 3 to 7 | 57 | 53 |
| Month 9 — Score 1 or 2 | 21 | 27 |
| Month 9 — Scores 3 to 7 | 58 | 52 |
| Month 12 — Score 1 or 2 | 17 | 32 |
| Month 12 — Scores 3 to 7 | 62 | 47 |
Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo - TNX-102 SL 2.8 mg | 0/79 (0%) | 3/79 (3.8%) | 43/79 (54.4%) |
| TNX-102 SL 2.8mg - TNX-102 SL 2.8 mg | 0/79 (0%) | 5/79 (6.3%) | 39/79 (49.4%) |
| Event | Placebo - TNX-102 SL 2.8 mg | TNX-102 SL 2.8mg - TNX-102 SL 2.8 mg |
|---|---|---|
| AnxietyPsychiatric disorders | 0/79 | 1/79 |
| Intraductal proliferative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/79 | 1/79 |
| Abdominal herniaGastrointestinal disorders | 0/79 | 1/79 |
| Ankle fractureInjury, poisoning and procedural complications | 0/79 | 1/79 |
| Brain stem gliomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/79 | 1/79 |
| Pubic fractureInjury, poisoning and procedural complications | 1/79 | 0/79 |
| VertigoEar and labyrinth disorders | 1/79 | 0/79 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/79 | 0/79 |
| Event | Placebo - TNX-102 SL 2.8 mg | TNX-102 SL 2.8mg - TNX-102 SL 2.8 mg |
|---|---|---|
| Hypoaesthesia oralGastrointestinal disorders | 22/79 | 1/79 |
| SinusitisInfections and infestations | 1/79 | 10/79 |
| Product taste abnormalGeneral disorders | 9/79 | 0/79 |
| FatigueGeneral disorders | 3/79 | 8/79 |
| Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders | 0/79 | 6/79 |
| GlossodyniaGastrointestinal disorders | 5/79 | 2/79 |
| ConstipationGastrointestinal disorders | 2/79 | 4/79 |
| SomnolenceNervous system disorders | 1/79 | 4/79 |
| ParaesthesiaNervous system disorders | 0/79 | 4/79 |
| Age, Categorical(Participants) | Placebo - TNX-102 SL 2.8 mg | TNX-102 SL 2.8 mg - TNX-102 SL 2.8 mg | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 75 | 79 | 154 |
| >=65 years | 4 | 0 | 4 |
| Age, Continuous(Years) | Placebo - TNX-102 SL 2.8 mg | TNX-102 SL 2.8 mg - TNX-102 SL 2.8 mg | Total |
|---|---|---|---|
| Mean | 50.2 (19 to 65) | 51.7 (20 to 64) | 50.9 (19 to 65) |
| Sex: Female, Male(Participants) | Placebo - TNX-102 SL 2.8 mg | TNX-102 SL 2.8 mg - TNX-102 SL 2.8 mg | Total |
|---|---|---|---|
| Female | 78 | 75 | 153 |
| Male | 1 | 4 | 5 |
Plan to share: Undecided
No publications or documents are linked to this record.
The record gives a start of Dec 2013, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2017, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclobenzaprine